Precept Management’s IN8bio INAB Stock Holding History

Precept Management’s Portfolio INAB Stock Details INAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,667	Closed	-$101K	–	20
2022 Q3	$101K	Buy	+1,667	New	+$112K	0.72%	16

Other funds holding INAB

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

SIG

Stonegate Investment Group Birmingham, Alabama $4.31B AUM 18.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

RCG

Rock Creek Group Washington, District of Columbia $988M AUM 8.89% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Precept Management's INAB Position: Q4 2022 in Review

Precept Management sold out of IN8bio (INAB) in Q4 2022, closing a stake of 1,667 shares — an estimated $101K sold.

Precept Management first reported a position in INAB in Q3 2022 and held it in 1 quarter. The position peaked at $101K in Q3 2022. 16 funds tracked by Wall St. Rank hold INAB as of Q4 2022.

Precept Management reported no remaining IN8bio position as of Q4 2022 after selling out during the quarter.
Precept Management sold 1,667 IN8bio shares in Q4 2022, an estimated $101K.
Precept Management first reported a position in IN8bio in Q3 2022 and held it in 1 quarter.
Precept Management's IN8bio position peaked at $101K in Q3 2022.
16 funds tracked by Wall St. Rank held IN8bio as of Q4 2022.

Based on Precept Management's 13F filing for Q4 2022, filed 14 Feb 2023.